Spots Global Cancer Trial Database for A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
Official Title: A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection in Subjects With Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas
Study ID: NCT04569838
Conditions
Interventions
Study Description
Brief Summary: This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fujian Cancer Hospital, Fuzhou, Fujian, China
First People's Hospital of Foshan, Foshan, Guangdong, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China
Shenzhen People's Hospital, Shenzhen, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
